Citations

Clear

941 citation(s) found for "Tan, MH".

Point of care molecular cancer diagnostics
Bhaskar, Seemesh , Umrao, Saurabh , Lee, Han Keun , Tibbs, Joseph , Bacon, Amanda , Shepherd, Skye , Ayupova, Takhmina , Ciloglu, Fatma Uysal , Liu, Leyang , Tan, Anqi , Chen, Wang-Chien , Nguyen, My Thi Tra , Scannell, Maria Grace , Aygün, Uğur , Zhang, Catherine, Adami, Guy R. , Badar, Wali, Gaba, Ron C. , Mansfield, A., Schwartz, Joel L., XING, WANG, Demirci, Utkan, Parlatan, Ugur , Zhang, Catherine , Kohli, Manish , Adami, Guy R , Badar, Wali , Gaba, Ron C , Mansfield, Aaron S , Schwartz, Joel , Xing, Wang , Demirci, Utkan , Cunningham, Brian T , Kohli, Manish , Mansfield, Aaron S. , Demirci, Utkan , Cunningham, Brian T.

Mayo Clinic

Lab on a Chip | February 10, 2026 | Volume: 26 | Issue: 10 | Pages: 2948-3001

10.1039/d5lc01014d | PMID 41811171 Get It

Convergent framework for future POC cancer diagnostics aligning clinical needs (why), enabling technologies (how), and translational bridges. It integrates lab-on-chip biosensing and analytics for decentralized, early, longitudinal care.
Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?
Tan, Po Hong, Thiels, Cornelius A., Poruk, Katherine E. , Miller, R., Hor, Hoe Yan , Tu, Melody Pi Yin , Huyser, Michelle R., Stucky, Chee-Chee, Wasif, Nabil , Bold, Richard J. , Smoot, R., Starlinger, Patrick P., Warner, Susanne G., Kendrick, M., Stauffer, John A., Truty, M., Fong, Zhi Ven, _, _, Poruk, Katherine, Miller, Richard Max, Thiels, Cornelius A. , Stucky, Chee‐Chee , Starlinger, Patrick , Warner, Susanne G. , Kendrick, Michael L. , Stauffer, John , Truty, Mark J. , Fong, Zhi Ven

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 27-33

10.6004/jnccn.2025.7097 | PMID 41671431 Get It

Background: Upfront resectable pancreatic ductal adenocarcinoma (PDAC) is defined by the NCCN as disease with ≤180° portomesenteric vein (PMV) abutment. However, the clinical significance of PMV abutment in this cohort remains unexplored, and we sought to investigate its impact. Methods: This multi-institutional study included patients who underwent pancreatoduodenectomy (PD) for upfront resectable PDAC from 2002 to 2023. Patients with PDAC with ≤180° PMV abutment were compared with those without. Overall survival (OS) was compared and stratified based on whether patients underwent upfront surgery or neoadjuvant therapy (NAT). Results: Among 1,446 patients included, 521 (36.0%) had PMV abutment. Median OS for patients with PMV abutment was 28.8 months compared with 31.2 months for those without ( P =.17). In a stratified analysis of patients who underwent upfront surgery, patients with PMV abutment had worse OS (19.2 vs 27.6 months; P <.05) and lower R0 resection rates (63.1% vs 87.2%; P <.05) compared with those without. However, in patients who underwent NAT, this difference in R0 resection rate was not observed (91.4% vs 94.0%, respectively; P =.27). Furthermore, there was no significant difference in median OS with NAT (42.5 vs 51.6 months, respectively; P =.48). Conclusions: In this largest cohort to date of patients with upfront resectable PDAC, PMV abutment was associated with worse OS compared with no PMV abutment when an upfront resection strategy was used. The use of NAT in patients with PMV abutment mitigated this survival difference with increased R0 resection rates. These findings suggest that patients with upfront resectable PDAC with PMV abutment benefit from a NAT approach for optimal survival outcomes, and that the current criteria guidelines need to be redefined.
RUNX1 is a mediator of fibrotic activation and epigenetic memory in lung fibroblasts
Gilbert, Rachel M. , Meridew, Jeffrey A., Choi, K., Haak, Andrew J. , Link, Patrick A. , Ördög, Tamás , Ligresti, Giovanni , Tschumperlin, Daniel J. , Jones, Dakota L. , Wellmerling, Jack , Ordog, Tamas , Link, Patrick A , Caporarello, Nunzia , Tan, Qi , Lee, Jeong‐Heon

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | February 6, 2026 | Volume: 74 | Issue: 7 | Pages: 911-923

10.1093/ajrcmb/aanag022 | PMID 41738205 Get It

Abstract Repetitive injury is hypothesized to lead to progressive tissue fibrosis and end-stage organ failure. Whether tissue-resident mesenchymal cell populations retain epigenetic memory of prior injuries that contribute to this pathological process is unknown. Here we used a genetic lineage labeling approach to mark the lung mesenchyme prior to injury, then performed multimodal analyses on isolated lung mesenchyme during the initiation, progression, and resolution of the fibrotic response. Our results demonstrate the remarkable epigenetic and transcriptional plasticity of the lung mesenchyme during fibrotic activation and de-activation. Despite this plasticity, we also find that the lung mesenchyme exhibits an enhanced fibrotic program upon reinjury. We identify RUNX1 as a critical driver of both fibrotic activation and fibrotic memory. Comparison of fresh isolated and cultured lung mesenchyme demonstrates that RUNX1 is spontaneously activated in standard culture conditions, previously masking these roles of RUNX1. Targeted knockdown of RUNX1 dampens fibrotic mesenchymal cell activation immediately after cell isolation, but with reduced efficacy after only days of culture, confirming its functional importance to both early activation and long-term memory. Collectively, our findings implicate RUNX1 in the initiation and memory of fibrotic mesenchymal cell activation that together prime enhanced mesenchymal cell responses upon repeated injury.
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Srinagesh, Hrishikesh K. , Zhang, Amy, Grunwald, Michael R, Connor, Matthew P, Kota, Vamsi, Boccucci, Jacob , Ulrickson, M., Pradeep, Roshini , Hill, L, Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Sandhu, Karamjeet , Gordillo, Christian , Chen, Evan C., Lin, Chenyu, Kopmar, Noam E. , Majhail, Navneet S. , Lee, C F, Bobillo, Silvina Odstrcil, Park, Jae H, Valtis, Yannis K. , Solh, Melhem M, Guzowski, Caitlin, Vasu, Sumithira, Tan, Virginia, McCauley, Ross , Sasine, Joshua , Tang, Kevin, Kk, Miller, Sutherland, Katherine C. , Mohty, Razan , Jamy, Omer , Hoeg, Rasmus T., Logan, Aaron, Stock, Wendy A, Schwartz, Marc S., Byrd, Kenneth, Bachanova, Veronika, Tracy, Sean , Yaghmour, George , Gatell, Vivian Irizarry , Jackson, Clayton, Dholaria, Bhagirathbhai, O'Dwyer, Kristen M, Moore, Jozal , Aldoss, Ibrahim, Shah, B. D., Oliai, Caspian , Muffly, Lori, Grunwald, Michael R. , Kota, Vamsi , Bachanová, Veronika , Muffly, Lori , Hill, LaQuisa C. , Zhang, Amy , Connor, Matthew P. , Zhang, Amy , Grunwald, Michael , Connor, Matthew , Kota, Vamsi , Ulrickson, Matthew , Pradeep, Roshini , Hill, LaQuisa C , Advani, Anjali S , Reshef, Ran , Luskin, Marlise R , Chen, Evan , Lin, Chenyu , Cassaday, Ryan D , Kopmar, Noam E , Majhail, Navneet S , Battiwalla, Minoo , Strickland, Stephen Anthony , Lee, Catherine J , Odstrcil Bobillo, Silvina , Hilal, Talal , Faramand, Rawan , Leonard, Jessica T , Wang, Eunice S. , Sasine, Joshua , Sutherland, Katherine , Daunov, Michael , Jamy, Omer , Dykes, Kaitlyn C , Logan, Aaron C , Othman, Tamer , Stock, Wendy , Yalniz, Fevzi , Bachanova, Veronika , Irizarry Gatell, Vivian M , Oluwole, Olalekan O , Dholaria, Bhagirathbhai R , O'Dwyer, Kristin , Moore, Jozal , Roloff, Gregory W , Frey, Noelle V , Shah, Bijal , Oliai, Caspian H , Muffly, Lori , Gupta, Vishal , Ulrickson, Matthew L. , Tsai, Stephanie, Advani, Anjali S. , Reshef, Ran , Lin, Chenyu , Cassaday, Ryan D. , Battiwalla, Minoo , Bobillo, María Silvina Odstrcil , Hilal, Talal , Park, Jae H. , Faramand, Rawan , Solh, Melhem , Vasu, Sumithira , Daunov, Michael , Kumaran, Muthu Sendhil , Hoeg, Rasmus T. , Dykes, Kaitlyn C. , Othman, Tamer , Stock, Wendy , Byrd, Kenneth, Yalniz, Fevzi , Jackson, Clayton W., Oluwole, Olalekan O. , Dholaria, Bhagirathbhai , Roloff, Gregory W. , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood | February 5, 2026 | Volume: 147 | Issue: 17 | Pages: 2011-2017

10.1182/blood.2025031734 | PMID 41643192 Get It

Abstract In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.
Atrial fibrillation and flutter conversion with pulsed electric field delivery: preclinical proof of concept
Tan, N, Munoz, F Del-Carpio, Tri, Jason , Koya, T, Otsuka, Naoto , Desimone, C, Yalamuri, S, Maor, Elad, Miklavcic, D, Asirvatham, S, Munoz, Freddy Del‐Carpio , Koya, Taro , DeSimone, Christopher V. , Yalamuri, Suraj , Maor, Elad , Castellví, Quim , Ivorra, Antoni , Miklavčič, Damijan , Asirvatham, Samuel J.

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.786 Get It

Abstract Background Many patients with atrial fibrillation (AF) suffer life-limiting symptoms and heart failure. Although enormous advances in rhythm control have been made, device-based therapies for treating recurrent episodes are limited. Using pulsed electric fields (PEF) to induce reversible electroporation of cardiac tissue may effectively terminate AF. Purpose To assess the feasibility of PEF delivery for converting atrial arrhythmias via reversible electroporation. Methods Four swine models were used in this acute study. Custom-made decapolar catheters for PEF delivery were deployed with the following configurations: 1. Endocardial right atrium (RA) and coronary sinus (CS), n=2; 2. Endocardial RA and epicardial left atrium (epiLA), n=2. AF and atrial flutter (AFL) were induced with programmed stimulation. PEF delivery was performed using the BTX 830 generator. For each attempt, a single monophasic pulse at 10 or 20µs pulse width was administered, with voltage varied across attempts (range 750-3000V). Successful (type 1 and 2 breaks) and unsuccessful conversion attempts were recorded. Post-PEF signal changes and arrhythmias were identified. Results A total of 58 AF/AFL (28 and 30 respectively) episodes were induced. Of the 37 successful conversion attempts, 33 (89.1%) were type 1 breaks. Conversion success probabilities generally increased with higher voltages for both configurations. &gt;70% conversion success was seen with ≥1500V for the RA/CS configuration and ≥2000V for the RA/epiLA configuration. Arrhythmias including intra-atrial delay and high-grade atrioventricular block were seen, usually following successive PEF deliveries. Significant muscle stimulation was provoked with the current experimental setup. Conclusion Termination of atrial arrhythmias with PEF delivery is feasible, although further work is required to optimize its efficacy and safety.
Ventricular pulsed field defibrillation: preclinical feasibility study
Tan, N, Munoz, F Del-Carpio, Tri, Jason , Koya, T, Otsuka, Naoto , Desimone, C, Yalamuri, S, Maor, Elad, Miklavcic, D, Asirvatham, S, Munoz, Freddy Del‐Carpio , Koya, Taro , DeSimone, Christopher V. , Yalamuri, Suraj , Maor, Elad , Castellví, Quim , Ivorra, Antoni , Miklavčič, Damijan , Asirvatham, Samuel J.

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.788 Get It

Abstract Background Ventricular fibrillation (VF) is a leading cause of sudden cardiac death worldwide. Defibrillation via direct current shocks is effective but associated with significant pain and morbidity, prompting the need for alternative approaches. Reversible electroporation of cardiac tissue with pulsed electric fields (PEF) may be an effective means of terminating VF. Purpose To assess the feasibility of PEF delivery for terminating VF. Methods 5 acute swine models were used. Mechanical circulatory support with peripheral veno-arterial extracorporeal membrane oxygenation +/- percutaneous left ventricular assist device (Impella 5.5 L) was implemented and titrated to a mean arterial pressure ≥65 mmHg. Decapolar catheters were introduced into the endocardial right and/or left ventricle as well as epicardium. VF was induced with R on T shocks or rapid ventricular pacing. PEF was delivered with the endocardial catheter as the cathode and epicardial catheter as the anode; monophasic pulses (5-10) at 3000V, 100µs, and 200ms inter-pulse intervals were used. If VF persisted post-PEF, catheters were repositioned into regions of intact voltages for repeat delivery. Results 10 VF episodes were induced, 7 of which were successfully terminated with PEF delivery (70.0%). The median number of attempts to achieve VF termination was 2 (range 1-5). The post-VF rhythm was complete heart block with ventricular asystole in all successful defibrillation attempts, with no recovery after 30 minutes of observation. Significant muscle stimulation was seen with the utilized PEF parameters and catheter configurations. Conclusion Termination of VF using PEF – pulsed field defibrillation – is possible. However, further study is required to optimize delivery parameters/configurations to improve effectiveness and avoid muscle stimulation as well as conduction abnormalities.
Association of Premature Ventricular Contraction with Atrial Fibrillation Ablation Outcomes
Yee, Min , Yeo, Yong Hao , Habib, Eiad, Sorajja, Dan , Yee, Ming Fong, Tan, Min Choon , Yeo, Yong Hao , Vignarajah, Aravinthan , Baqal, Omar J , Habib, Eiad , Srivathsan, Komandoor , Masry, Hicham El

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8653344/v1 Get It

Abstract Background Emerging evidence suggests that premature ventricular contractions (PVCs) may influence atrial electrophysiology and remodeling, potentially leading to higher rates of atrial fibrillation (AF) recurrence. However, existing data is limited to small-scale studies. Therefore, we conducted a retrospective study to evaluate the potential association between PVCs and AF ablation outcomes, which may suggest the need for more aggressive management of ventricular ectopy in this population. Objective This study aims to assess the 5-year outcomes of catheter ablation for AF in patients with and without a diagnosis of PVCs. Methods Using the TriNetX Analytics Research Network, we included patients aged ≥ 18 years who underwent AF catheter between January 1, 2014, and January 1, 2020. Patients were further categorized into two groups based on the presence of a diagnosis of PVCs. Propensity score matching (PSM) was performed using patient demographics, left ventricular ejection fraction (LVEF), cardiac comorbidities, and medications. Study outcomes included all-cause mortality & hospitalization, acute heart failure (HF), and rhythm control interventions during a 5-year follow-up. Results A total of 15,987 patients with PVCs and 40,605 patients without PVCs were identified. After PSM, 15,152 patients from each group were included for further analysis. Compared to control group, patients with PVCs had significantly higher odds of all-cause mortality (odds ratio [OR], 1.138; 95% confidence interval [CI], 1.034–1.253), all-cause hospitalization (OR, 1.300; 95% CI, 1.243–1.360), acute heart failure (HF) (OR, 1.223; 95% CI, 1.162–1.287), and cardiogenic shock (OR, 2.059; 95% CI, 1.751–2.420) following catheter ablation for AF at 5-year follow-up. Additionally, higher odds of AF requiring cardioversion (OR, 1.135; 95% CI, 1.074–1.199) or repeated ablation (OR, 1.164; 95% CI, 1.085–1.249) were observed in the PVCs group. Conclusion Premature ventricular contractions were associated with poorer clinical outcomes and a higher odds of requiring additional rhythm control intervention following catheter ablation for AF. These findings suggest that PVCs may be a marker for worse outcomes after AF ablation.
Epigenetic Regulation of Higher-Order Chromatin Structure (HOCS) and Its Implication in Human Diseases
Ladel, Luisa, Sailo, Bethsebie, Das, Paromita, Tan, Wan Ying , Chhoda, Ankit , Tang, Haoyu, Ang-Olson, Olivia, He, Linda, John, Nithyla, Kratz, Jeremy D. , Sharma, Anup , Ahuja, Nita, Ang-Olson, Olivia , Kratz, Jeremy D , Lin, Ethan Samuel , Tang, Haoyu , Ahuja, Nita

Mayo Clinic

Cancers | February 2, 2026 | Volume: 18 | Issue: 3 | Pages: 483

10.3390/cancers18030483 | PMID 41681953 Get It

Higher-order chromatin structures (HOCS) are fundamental to genome organization, gene regulation, and cellular homeostasis. This review examines the epigenetic mechanisms shaping HOCS, including DNA methylation, histone modifications, chromatin remodeling, and RNA-based regulatory processes. We also discuss the role of architectural proteins in maintaining chromatin topology while allowing dynamic changes to chromatin structure, thereby influencing gene expression. Growing evidence indicates that disruptions in HOCS contribute to a diverse array of human diseases, including cancer, aging-related disorders, and congenital abnormalities, primarily through aberrant gene regulation. We further discuss the concept of distinct genomic areas, in which specific chromatin regions orchestrate three-dimensional (3D) genome dynamics, positioning them as potential biomarkers and therapeutic targets. By emphasizing chromatin architecture on a global scale rather than at the level of individual genes, this review underscores its emerging relevance to precision medicine. Finally, we synthesize current technical advances, outline future directions for leveraging chromatin topology in disease diagnosis and treatment, and highlight key biological insights to reshape our understanding of genome function.
Multisystemic Imaging Features of Coccidioidomycosis
Haug, Logan P. , Lang, Harrison, Naeem, Muhammad, Kawashima, Akira , Jokerst, Clinton, Ikuta, Ichiro , Long, Jeremiah R. , Sugi, Mark, Yano, Motoyo , Tan, Nelly , Zulfiqar, Maria, Kawashima, Akira , Sugi, Mark , Jokerst, Clinton E , Sugi, Mark D , Zulfiqar, Maria , Long, Jeremiah , Ikuta, Ichiro , Lang, Harrison

Mayo Clinic

RadioGraphics | January 29, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250064 | PMID 41610037 Get It

An understanding of regions of endemicity and the spectrum of organ system involvement can improve recognition of the imaging features of coccidioidomycosis, which can overlap with those of other diseases.
From first generation to the next: evolution and research trends in iStent technology
Ang, Bryan Chin Hou, Wong, Natalie Shi Qi , Lim, Sheng Yang , Ang, Bryan C H , Betzler, Bjorn Kaijun

Mayo Clinic

Frontiers in Medicine | January 23, 2026 | Volume: 12 | Issue: No issue available | Pages: No page available

10.3389/fmed.2025.1724886 | PMID 41657563 Get It

The iStent series constitutes a range of trabecular bypass minimally invasive glaucoma surgery (MIGS) devices, which offers intraocular pressure (IOP) reduction with favourable safety profiles, in patients with open-angle glaucoma (OAG). Having undergone significant evolution since its initial US FDA-approval in 2012, successive generations address previous limitations, while enhancing IOP-lowering efficacy through device and delivery system design iterations. Longer-term and real-world iStent data demonstrate the durability of IOP- and medication-lowering outcomes with minimal complications, while preliminary studies across a wider spectrum of glaucoma subtypes and severities provide limited evidence of successful outcomes beyond mild-to-moderate OAG, both with and without concomitant cataract surgery. Aqueous humour outflow assessment and novel intra-operative techniques may further facilitate more accurate and effective iStent positioning. Despite typically higher upfront costs, results from both cost-effectiveness and patient-reported outcome studies are encouraging. Combination MIGS with the iStent, leveraging on the multiple mechanisms of actions of various procedures, may provide greater IOP-lowering efficacy without compromising safety. With expanding clinical data and progressive enhancements, iStent technology is likely to remain a key component of the evolving MIGS landscape.